Skip to main content

letter

. 1981 Oct;12(4):585–588. doi: 10.1111/j.1365-2125.1981.tb01271.x

Comparison of single and divided daily dose spironolactone in the control of hypertension.

G M Bell, L Fananapazir, J L Anderton

PMCID: PMC1401883 PMID: 7295494

585

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Dahlöf C. G., Lundborg P., Persson B. A., Regårdh C. G. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method. Drug Metab Dispos. 1979 Mar-Apr;7(2):103–107. [PubMed] [Google Scholar]
GOCHMAN N., GANTT C. L. A fluorimetric method for the determination of a major spironolactone (Aldactone) metabolite in human plasma. J Pharmacol Exp Ther. 1962 Mar;135:312–316. [PubMed] [Google Scholar]
KAGAWA C. M., BOUSKA D. J., ANDERSON M. L. RELATIONSHIP OF PLASMA ALDADIENE LEVELS AND ANTIMINERALOCORTICOID EFFECTS OF SPIRONOLACTONE IN THE LABORATORY. Proc Soc Exp Biol Med. 1964 Mar;115:837–840. doi: 10.3181/00379727-115-29052. [DOI] [PubMed] [Google Scholar]
Karim A., Zagarella J., Hribar J., Dooley M. Spironolactone. I. Disposition and metabolism. Clin Pharmacol Ther. 1976 Feb;19(2):158–169. doi: 10.1002/cpt1976192158. [DOI] [PubMed] [Google Scholar]
Karim A., Zagarella J., Hutsell T. C., Dooley M. Spironolactone. III. Canrenone--maximum and minimum steady-state plasma levels. Clin Pharmacol Ther. 1976 Feb;19(2):177–182. doi: 10.1002/cpt1976192177. [DOI] [PubMed] [Google Scholar]
Ludbrook A., Dynon M., Mendelsohn F. A., Louis W. J. Comparison of a single-dose and twice-a-day spironolactone therapy in mild hypertension. Med J Aust. 1980 Feb 9;1(3):124–125. doi: 10.5694/j.1326-5377.1980.tb134686.x. [DOI] [PubMed] [Google Scholar]
Ochs H. R., Greenblatt D. J., Bodem G., Smith T. W. Spironolactone. Am Heart J. 1978 Sep;96(3):389–400. doi: 10.1016/0002-8703(78)90052-2. [DOI] [PubMed] [Google Scholar]
Ogilvie R. I., Piafsky K. M., Ruedy J. Antihypertensive responses to spironolactone in normal renin hypertension. Clin Pharmacol Ther. 1978 Nov;24(5):525–530. doi: 10.1002/cpt1978245525. [DOI] [PubMed] [Google Scholar]
Ramsay L., Asbury M., Shelton J., Harrison I. Spironolactone and canrenoate-K: relative potency at steady state. Clin Pharmacol Ther. 1977 May;21(5):602–609. doi: 10.1002/cpt1977215602. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES